• 1
    Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002; 156: 10707.
  • 2
    Sattar N, Gaw A, Scherbakova O et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108: 4149.
  • 3
    Hanley AJ, Karter AJ, Williams K et al. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the insulin resistance atherosclerosis study. Circulation 2005; 112: 371321.
  • 4
    Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care 2003; 26: 31539.
  • 5
    Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 2004; 27: 267681.
  • 6
    Wilson PW, D’Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112: 306672.
  • 7
    Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med 2005; 165: 264450.
  • 8
    Schmidt MI, Duncan BB, Bang H et al. Identifying individuals at high risk for diabetes: the atherosclerosis risk in communities study. Diabetes Care 2005; 28: 20138.
  • 9
    Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program-Adult Treatment Panel III, International Diabetes Federation, and World Health Organization Definitions of the Metabolic Syndrome as Predictors of Incident Cardiovascular Disease and Diabetes. Diabetes Care 2007; 30: 813.
  • 10
    Dunstan DW, Zimmet PZ, Welborn TA et al. The Australian Diabetes, Obesity and Lifestyle Study (AusDiab) – methods and response rates. Diabetes Res Clin Pract 2002; 57: 11929.
  • 11
    Barr L, Magliano D, Zimmet P, et al. AusDiab 2005. The Australian Diabetes, Obesity and Lifestyle Study. Tracking the Accelerating Epidemic: Its Causes and Outcomes. Melbourne: International Diabetes Institute, 2006.
  • 12
    World Health Organisation. Defintion, Diagnosis and Classification of Diabetes Mellitus and its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva: Department of Non-communicable Diseases Surveillance, World Health Organization, 1999.
  • 13
    Cameron AJ, Welborn TA, Zimmet PZ et al. Overweight and obesity in Australia: the 1999-2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Med J Aust 2003; 178: 42732.
  • 14
    Briganti EM, Shaw JE, Chadban SJ et al. Untreated hypertension among Australian adults: the 1999-2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Med J Aust 2003; 179: 1359.
  • 15
    World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications; Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva: Department of Noncommunicable Disease Surveillance, 1999.
  • 16
    Alberti KG, Zimmet P, Shaw J. Metabolic syndrome – a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23: 46980.
  • 17
    Balkau B, Charles MA, Drivsholm T et al. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002; 28: 36476.
  • 18
    NCEP/ATP I. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 248697.
  • 19
    Levy J, Matthews D, Hermans M. Correct Homeostatic Model Assessment (HOMA) Evaluation Uses the Computer Program. Diabetes Care 1998; 21: 21912.
  • 20
    Lindstrom J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 2003; 26: 72531.
  • 21
    Australian Institute of Health and Welfare (AIHW). The Active Australia Survey. A guide and manual for implementation, analysis and reporting. , 2003.
  • 22
    Brown WJ, Trost SG, Bauman A, Mummery K, Owen N. Test-retest reliability of four physical activity measures used in population surveys. Journal of science and medicine in sport / Sports Medicine Australia 2004; 7: 20515.
  • 23
    Stern MP, Williams K, Haffner SM. Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med 2002; 136: 57581.
  • 24
    McNeely MJ, Boyko EJ, Leonetti DL, Kahn SE, Fujimoto WY. Comparison of a clinical model, the oral glucose tolerance test, and fasting glucose for prediction of type 2 diabetes risk in Japanese Americans. Diabetes Care 2003; 26: 75863.
  • 25
    Williams JW, Zimmet PZ, Shaw JE et al. Gender differences in the prevalence of impaired fasting glycaemia and impaired glucose tolerance in Mauritius. Does sex matter?. Diabet Med 2003; 20: 91520.
  • 26
    Norton EC, Wang H, Ai C. Computing interaction effects and standard errors in logit and probit models. Stata J 2004; 4: 15467.
  • 27
    Brotman DJ, Walker E, Lauer MS, O’Brien RG. In search of fewer independent risk factors. Arch Intern Med 2005; 165: 13845.
  • 28
    Tuomilehto J, Lindstrom J, Eriksson J et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 134350.
  • 29
    Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393403.